Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Jennifer Diamond

Concepts (287)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Triple Negative Breast Neoplasms
16
2024
202
6.420
 Why?
Breast Neoplasms
24
2025
2253
4.270
 Why?
Immunoconjugates
7
2023
114
2.500
 Why?
Antineoplastic Agents
23
2023
2129
2.490
 Why?
Antineoplastic Combined Chemotherapy Protocols
20
2025
1692
2.450
 Why?
Pyrimidines
9
2021
470
2.320
 Why?
Receptor, ErbB-2
12
2025
341
2.080
 Why?
Protein Kinase Inhibitors
11
2025
916
1.820
 Why?
Piperazines
4
2020
350
1.640
 Why?
Paclitaxel
6
2022
230
1.560
 Why?
Camptothecin
9
2023
116
1.560
 Why?
Neoplasms
14
2022
2671
1.510
 Why?
Pyrazoles
6
2021
423
1.350
 Why?
Ovarian Neoplasms
5
2025
565
1.300
 Why?
Quinoxalines
2
2020
66
1.280
 Why?
Antibodies, Monoclonal, Humanized
10
2024
804
1.230
 Why?
Azepines
3
2020
90
1.210
 Why?
Histone Deacetylase Inhibitors
4
2024
210
1.170
 Why?
Cyclin-Dependent Kinase 4
2
2018
47
1.070
 Why?
Cyclin-Dependent Kinase 6
2
2018
42
1.070
 Why?
Neutropenia
4
2022
146
0.860
 Why?
Gene Expression Regulation, Neoplastic
5
2020
1396
0.760
 Why?
Xenograft Model Antitumor Assays
11
2021
872
0.730
 Why?
Breast Neoplasms, Male
2
2018
29
0.720
 Why?
beta Catenin
2
2020
253
0.720
 Why?
Female
51
2025
73304
0.670
 Why?
Chemotherapy, Adjuvant
4
2023
389
0.670
 Why?
Maximum Tolerated Dose
9
2022
199
0.670
 Why?
Benzoxazoles
1
2020
19
0.670
 Why?
Cancer Care Facilities
1
2020
38
0.670
 Why?
Receptors, Estrogen
3
2021
436
0.670
 Why?
Carcinoma, Lobular
2
2018
49
0.660
 Why?
eIF-2 Kinase
1
2019
31
0.630
 Why?
Lymphocytes, Tumor-Infiltrating
2
2020
210
0.620
 Why?
Tumor Microenvironment
4
2024
674
0.610
 Why?
Anthracyclines
3
2023
42
0.600
 Why?
Humans
64
2025
137585
0.590
 Why?
Taxoids
3
2023
102
0.580
 Why?
Carcinoma, Ductal, Breast
1
2018
83
0.550
 Why?
Aged
24
2025
23961
0.550
 Why?
Aurora Kinase A
4
2020
56
0.550
 Why?
Drug Resistance, Neoplasm
4
2020
801
0.550
 Why?
Wnt Signaling Pathway
1
2019
192
0.550
 Why?
Trastuzumab
4
2023
96
0.550
 Why?
Pyridines
3
2025
506
0.540
 Why?
Pyrazines
2
2018
90
0.520
 Why?
Myocardial Infarction
1
2023
1046
0.500
 Why?
Colonic Neoplasms
1
2018
258
0.500
 Why?
Tumor Suppressor Protein p53
4
2024
528
0.480
 Why?
Neoadjuvant Therapy
1
2018
404
0.480
 Why?
Angiopoietin-1
1
2015
11
0.470
 Why?
Angiopoietin-2
1
2015
16
0.470
 Why?
Nuclear Proteins
2
2023
712
0.470
 Why?
Neoplasm Recurrence, Local
5
2025
1079
0.470
 Why?
Medicare
4
2023
773
0.430
 Why?
Uterine Cervical Neoplasms
1
2017
257
0.430
 Why?
Middle Aged
25
2025
33479
0.420
 Why?
Cell Line, Tumor
9
2022
3412
0.420
 Why?
Colorectal Neoplasms
5
2022
806
0.410
 Why?
Radiosurgery
3
2025
344
0.400
 Why?
Dose-Response Relationship, Drug
6
2022
2057
0.390
 Why?
Adult
26
2025
37929
0.390
 Why?
Antibodies, Monoclonal
4
2024
1430
0.390
 Why?
Tumor Suppressor Proteins
1
2015
327
0.390
 Why?
Treatment Outcome
13
2025
10811
0.390
 Why?
Proto-Oncogene Proteins c-met
1
2013
75
0.390
 Why?
Cell Proliferation
8
2020
2475
0.390
 Why?
Antineoplastic Agents, Immunological
3
2019
190
0.380
 Why?
Recombinant Fusion Proteins
1
2015
665
0.380
 Why?
Point Mutation
1
2013
235
0.380
 Why?
Triazoles
1
2013
147
0.370
 Why?
Angiogenesis Inhibitors
3
2018
229
0.360
 Why?
Aged, 80 and over
10
2025
7635
0.350
 Why?
Mice, Nude
6
2020
698
0.350
 Why?
Quinolines
3
2025
178
0.350
 Why?
Clinical Trials, Phase I as Topic
2
2020
50
0.340
 Why?
Carcinoma, Renal Cell
1
2013
217
0.340
 Why?
Mitochondria
1
2017
948
0.330
 Why?
Heart Failure
1
2023
2236
0.330
 Why?
Histones
3
2023
636
0.330
 Why?
Genes, BRCA2
1
2009
31
0.320
 Why?
Neoplasm Metastasis
4
2020
658
0.320
 Why?
Genes, BRCA1
1
2009
40
0.320
 Why?
Molecular Targeted Therapy
3
2019
411
0.310
 Why?
Biomarkers, Tumor
2
2014
1276
0.310
 Why?
BRCA2 Protein
1
2009
63
0.310
 Why?
Pregnancy Complications, Neoplastic
1
2009
52
0.310
 Why?
Thrombophilia
1
2009
83
0.300
 Why?
Neoplasm Staging
5
2021
1389
0.300
 Why?
Apoptosis
7
2024
2553
0.290
 Why?
Kidney Neoplasms
1
2013
403
0.290
 Why?
Lung Neoplasms
2
2024
2526
0.290
 Why?
Aromatase Inhibitors
2
2018
54
0.290
 Why?
Receptors, Progesterone
2
2021
350
0.280
 Why?
DNA-Binding Proteins
1
2015
1502
0.270
 Why?
Models, Biological
1
2014
1783
0.250
 Why?
Mice
9
2021
17787
0.250
 Why?
Doxorubicin
3
2024
362
0.240
 Why?
Cyclophosphamide
2
2018
247
0.210
 Why?
Disease Models, Animal
3
2021
4295
0.200
 Why?
United States
5
2023
14841
0.200
 Why?
Brain Neoplasms
3
2025
1238
0.200
 Why?
Liver Neoplasms
1
2009
786
0.200
 Why?
Cyclin-Dependent Kinase 9
1
2022
10
0.190
 Why?
Animals
11
2021
36940
0.190
 Why?
Biopsy
2
2018
1129
0.190
 Why?
Histone Deacetylase 1
1
2022
25
0.190
 Why?
Aurora Kinases
2
2012
27
0.190
 Why?
G2 Phase Cell Cycle Checkpoints
3
2022
44
0.190
 Why?
Administration, Oral
3
2022
816
0.190
 Why?
Topoisomerase I Inhibitors
2
2022
17
0.180
 Why?
Disease Progression
4
2019
2757
0.180
 Why?
Fluorouracil
1
2022
208
0.180
 Why?
Acetylation
1
2022
248
0.180
 Why?
Arrhythmias, Cardiac
1
2023
333
0.170
 Why?
Biliary Tract Neoplasms
1
2021
30
0.170
 Why?
Androstadienes
1
2021
107
0.170
 Why?
Diarrhea
2
2019
184
0.170
 Why?
Carboplatin
1
2021
144
0.170
 Why?
Heterografts
1
2021
138
0.170
 Why?
Hospitals, University
1
2021
182
0.170
 Why?
Drug Administration Schedule
3
2017
786
0.170
 Why?
Necrosis
2
2019
246
0.170
 Why?
Fatigue
2
2022
329
0.170
 Why?
Histone Deacetylases
1
2022
215
0.170
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
62
0.160
 Why?
Immunotherapy
2
2023
641
0.160
 Why?
Clinical Trials as Topic
3
2016
1050
0.160
 Why?
Immune System
1
2021
177
0.160
 Why?
Benzodiazepines
1
2021
155
0.160
 Why?
Male
13
2021
67762
0.160
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2020
125
0.160
 Why?
Myeloid Cell Leukemia Sequence 1 Protein
1
2019
41
0.160
 Why?
Kaplan-Meier Estimate
1
2021
889
0.150
 Why?
Tumor Cells, Cultured
1
2020
955
0.150
 Why?
Albumins
1
2019
114
0.150
 Why?
Aquaporin 4
1
2019
94
0.150
 Why?
Maintenance Chemotherapy
1
2018
35
0.150
 Why?
Aminopyridines
1
2018
98
0.140
 Why?
Nausea
1
2018
111
0.140
 Why?
Vascular Endothelial Growth Factor A
2
2018
545
0.140
 Why?
Antibodies, Bispecific
1
2018
55
0.140
 Why?
Mice, Inbred BALB C
1
2020
1272
0.140
 Why?
Radiotherapy, Adjuvant
1
2018
220
0.140
 Why?
Breast
1
2018
151
0.140
 Why?
Drug Therapy, Combination
1
2020
1066
0.140
 Why?
Purines
1
2018
176
0.140
 Why?
Benzimidazoles
1
2018
170
0.140
 Why?
Mastectomy
1
2018
137
0.140
 Why?
Topotecan
1
2017
13
0.140
 Why?
Isoflavones
1
2017
26
0.130
 Why?
Imidazoles
1
2018
238
0.130
 Why?
Calcium-Binding Proteins
1
2018
218
0.130
 Why?
Survival Analysis
1
2020
1325
0.130
 Why?
Carbolines
1
2017
32
0.130
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2017
20
0.130
 Why?
Inhibitory Concentration 50
2
2016
90
0.130
 Why?
Programmed Cell Death 1 Receptor
1
2019
249
0.130
 Why?
Retrospective Studies
4
2025
15657
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
92
0.130
 Why?
Cell Survival
1
2019
1120
0.120
 Why?
Insulin-Like Growth Factor I
1
2018
319
0.120
 Why?
Hypertension
2
2018
1295
0.120
 Why?
GPI-Linked Proteins
1
2016
73
0.120
 Why?
Adaptor Proteins, Signal Transducing
1
2018
430
0.120
 Why?
Neoplasms, Second Primary
1
2016
118
0.120
 Why?
Tumor Protein p73
1
2015
14
0.120
 Why?
Antibodies, Neoplasm
1
2015
34
0.120
 Why?
Carcinoma, Non-Small-Cell Lung
1
2024
1081
0.120
 Why?
Nanoparticles
1
2021
481
0.120
 Why?
Hodgkin Disease
1
2016
138
0.110
 Why?
Risk Reduction Behavior
1
2016
220
0.110
 Why?
Phosphorylation
1
2019
1759
0.110
 Why?
Maytansine
1
2014
16
0.110
 Why?
Demography
1
2015
291
0.110
 Why?
Brain Edema
1
2014
61
0.110
 Why?
Protein Kinases
1
2015
319
0.100
 Why?
Drug Interactions
1
2015
410
0.100
 Why?
Survival Rate
2
2019
1972
0.100
 Why?
Sulfones
1
2014
110
0.100
 Why?
Threonine
1
2013
47
0.100
 Why?
Randomized Controlled Trials as Topic
1
2019
1477
0.100
 Why?
Tumor Stem Cell Assay
1
2012
34
0.100
 Why?
Glycine
1
2014
176
0.100
 Why?
Drug Evaluation, Preclinical
1
2013
184
0.100
 Why?
Time Factors
2
2020
6828
0.100
 Why?
Analgesics, Opioid
1
2021
1000
0.100
 Why?
Drug Design
1
2013
167
0.100
 Why?
Methionine
1
2013
160
0.100
 Why?
Heterozygote
1
2013
293
0.090
 Why?
Disease-Free Survival
1
2014
686
0.090
 Why?
Treatment Failure
1
2013
356
0.090
 Why?
In Situ Hybridization, Fluorescence
1
2013
317
0.090
 Why?
Neovascularization, Pathologic
1
2013
301
0.090
 Why?
Cell Transformation, Neoplastic
1
2013
327
0.090
 Why?
Cluster Analysis
1
2012
499
0.090
 Why?
Receptor Protein-Tyrosine Kinases
1
2013
234
0.090
 Why?
Carcinoma in Situ
1
2011
49
0.090
 Why?
Computational Biology
1
2015
644
0.090
 Why?
Risk Assessment
1
2020
3457
0.090
 Why?
Cellular Senescence
1
2012
189
0.090
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2010
86
0.080
 Why?
Colorado
1
2020
4565
0.080
 Why?
Sequence Analysis, DNA
1
2013
812
0.080
 Why?
Mutation
2
2012
3958
0.080
 Why?
Tumor Burden
1
2010
309
0.080
 Why?
Pregnancy Trimester, Second
1
2009
80
0.080
 Why?
Keratinocytes
1
2010
249
0.080
 Why?
Mastectomy, Segmental
1
2009
93
0.080
 Why?
Pregnancy Trimester, First
1
2009
140
0.070
 Why?
Apoptosis Regulatory Proteins
1
2009
188
0.070
 Why?
Lymph Node Excision
1
2009
171
0.070
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
1
2009
115
0.070
 Why?
Risk
1
2009
912
0.070
 Why?
Infusions, Intravenous
2
2019
413
0.070
 Why?
Cell Adhesion Molecules
2
2019
181
0.070
 Why?
Prognosis
2
2018
4030
0.060
 Why?
Risk Factors
1
2020
10388
0.060
 Why?
Gene Expression Profiling
1
2012
1774
0.060
 Why?
Oxazoles
1
2025
37
0.060
 Why?
Antigens, Neoplasm
2
2019
319
0.060
 Why?
Cell Cycle Proteins
2
2023
617
0.060
 Why?
CD8-Positive T-Lymphocytes
2
2023
900
0.060
 Why?
Cell Cycle
2
2018
601
0.060
 Why?
Combined Modality Therapy
2
2019
1236
0.050
 Why?
Quinazolines
1
2025
251
0.050
 Why?
Follow-Up Studies
2
2025
5131
0.050
 Why?
Mesylates
1
2022
7
0.050
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2022
66
0.050
 Why?
Signal Transduction
2
2014
5079
0.050
 Why?
Clinical Protocols
1
2023
271
0.050
 Why?
Ligands
1
2024
664
0.050
 Why?
RNA, Small Interfering
1
2024
622
0.050
 Why?
Chimerism
1
2021
31
0.040
 Why?
Lymphocyte Subsets
1
2021
87
0.040
 Why?
Lymphoid Tissue
1
2021
75
0.040
 Why?
Liver
1
2009
1943
0.040
 Why?
Mice, SCID
1
2021
367
0.040
 Why?
Hormones
1
2020
143
0.040
 Why?
SEER Program
1
2021
227
0.040
 Why?
Mice, Inbred NOD
1
2021
601
0.040
 Why?
M Phase Cell Cycle Checkpoints
1
2018
24
0.040
 Why?
Tissue Distribution
1
2018
332
0.040
 Why?
Infant, Newborn
1
2009
6079
0.030
 Why?
Anemia
1
2019
170
0.030
 Why?
Pregnancy
1
2009
6763
0.030
 Why?
Cetuximab
1
2016
98
0.030
 Why?
Retreatment
1
2016
72
0.030
 Why?
Neoplasm Transplantation
1
2016
257
0.030
 Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2016
121
0.030
 Why?
Drug Screening Assays, Antitumor
1
2016
194
0.030
 Why?
Platinum
1
2016
50
0.030
 Why?
Hematopoietic Stem Cell Transplantation
1
2021
622
0.030
 Why?
History, Ancient
1
2015
54
0.030
 Why?
Proto-Oncogene Proteins p21(ras)
1
2016
267
0.030
 Why?
Transcription Factors
1
2023
1719
0.030
 Why?
Databases, Genetic
1
2015
237
0.030
 Why?
DNA Damage
1
2017
420
0.030
 Why?
Biomarkers
2
2016
4149
0.030
 Why?
Mice, Knockout
1
2021
3015
0.030
 Why?
Quality of Life
1
2025
2892
0.030
 Why?
Opioid-Related Disorders
1
2021
515
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2015
250
0.020
 Why?
Drug Combinations
1
2013
343
0.020
 Why?
Phenotype
1
2021
3196
0.020
 Why?
Intracellular Signaling Peptides and Proteins
1
2015
455
0.020
 Why?
Immunohistochemistry
1
2016
1738
0.020
 Why?
Biopsy, Needle
1
2011
189
0.020
 Why?
HT29 Cells
1
2010
41
0.020
 Why?
Transcription, Genetic
1
2017
1457
0.020
 Why?
Enzyme Inhibitors
1
2014
840
0.020
 Why?
Cohort Studies
1
2021
5742
0.020
 Why?
Proto-Oncogene Proteins
1
2014
648
0.020
 Why?
Protein-Tyrosine Kinases
1
2013
434
0.020
 Why?
ErbB Receptors
1
2013
614
0.020
 Why?
Ki-67 Antigen
1
2010
112
0.020
 Why?
Capillary Permeability
1
2010
145
0.020
 Why?
Patient Selection
1
2013
696
0.020
 Why?
Patient Satisfaction
1
2013
660
0.020
 Why?
Positron-Emission Tomography
1
2010
294
0.020
 Why?
Membrane Proteins
1
2015
1164
0.020
 Why?
Algorithms
1
2015
1704
0.020
 Why?
Magnetic Resonance Imaging
1
2019
3566
0.020
 Why?
Tomography, X-Ray Computed
1
2016
2691
0.010
 Why?
Adolescent
1
2024
21513
0.010
 Why?
Brain
1
2014
2668
0.010
 Why?
Young Adult
1
2014
13209
0.010
 Why?
Diamond's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (287) concept(s)
_
Co-Authors Expand Description
See all (74) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)